Non challengers | Challengers | p-value | Passive challengers | Aggressive challengers | p-value | |
---|---|---|---|---|---|---|
94 | 77 | 58 | 19 | |||
Innovative | ||||||
No | 85 | 57 | 0.0083 | 46 | 11 | 0.1221 |
Yes | 9 | 20 | 12 | 8 | ||
New drug | ||||||
No | 85 | 44 | < 0.0001 | 36 | 8 | 0.2080 |
Yes | 9 | 33 | 22 | 11 | ||
Sales | 87,321 (175,878) | 213,598 (271,251) | 0.0005 | 183,181 (263,621) | 306,449 (280,190) | 0.0856 |
Employees | 239 (339) | 515 (510) | < 0.0001 | 433 (436) | 765 (637) | 0.0448 |
Reimbursed drugs | 73 (76.7) | 189 (69.4) | < 0.0001 | 170 (56.9) | 248 (72.3) | < 0.0001 |